Table 4 Phases II trials evaluating carboplatin based doublets

Redman et al [28]

PCa

35

ORR = 51%; OS = 9.5 months

Small et al [29]

PCa

29

ORR = 20,7%; TTP = 4 months; OS = 9 months

Vaughn et al [30]

PCa

33

ORR = 50%

Bellmunt et al [32]

GCa

16

ORR = 44%

Nogue-Aliguer et al [33]

GCa

41

ORR = 56.1%; PFS = 7.2 months; OS = 10.1 months

Shannon et al [34]

GCa

17

ORR = 58.8%; PFS = 4.6 months; OS = 10.5 mois

Dogliotti et al [35]

GCa vs. GC (Randomized phase II)

110

Efficacy: CR: 1.8% vs. 14.5%; OS: 9.8 vs. 12.8 months

Toxicity: Equivalent.